Unichem Labs received USFDA approval for Pramipexole Dihydrochloride tablets

With this, the company can market a generic version of Boehringer Ingelheim Pharmaceutical’s Mirapex Tablets, 0.125mg, 0.25mg, 0.5mg, 0.75mg, 1mg, and 1.5mg.

Dec 24, 2018 03:12 IST India Infoline News Service

Unichem Laboratories
Unichem Laboratories in its filing to the exchanges informed that it has received final ANDA approval from USFDA for Pramipexole Dihydrochloride tablets 0.125mg, 0.25mg, 0.5mg, 0.75mg, 1mg, and 1.5mg. The announcement was made after market hours on Friday.

With this, the company can market a generic version of Boehringer Ingelheim Pharmaceutical’s Mirapex Tablets, 0.125mg, 0.25mg, 0.5mg, 0.75mg, 1mg, and 1.5mg.

Pramipexole Dihydrochloride tablets are indicated for the treatment of Parkinson's disease and also for the treatment of moderate to severe primary restless legs syndrome (RLS), the company added in the press note.

Unichem Laboratories Ltd's share price ended at Rs192.10 on Friday, up by Rs1.65 or 0.87%, from its previous close of Rs190.45 on the BSE.

The scrip opened at Rs190.85 and touched a high and low of Rs194.90 and Rs189.70, respectively. A total of, 58,097 (NSE+BSE) shares have traded on the counter. The current market cap of the company is Rs1,352.06cr.

Related Story